Celerion, Inc.

Celerion, Inc. is a clinical research organization specializing in early phase drug development services, offering comprehensive solutions in bioanalytical sciences and clinical trial management to pharmaceutical and biotechnology clients. Founded in 2010 in Lincoln, US, Celerion, Inc. focuses on early phase clinical research.

The company has successfully completed six deals, with the most recent funding round in October 2022, led by Bain Capital and SV Health Investors, raising a total of USD 45. 00 mn. Susan Thornton serves as both the Founder and CEO, bringing experience from her previous ventures. Celerion operates globally, with facilities in North America, Europe, and Asia, providing clinical trial services to a diverse client base.

Celerion offers a comprehensive range of early phase clinical research services, specializing in bioanalytical sciences and drug development solutions. Core services include clinical trial design, feasibility assessment, clinical monitoring, and data management, all aimed at optimizing the drug development process. Celerion employs advanced research technologies across therapeutic areas such as oncology, metabolic disease, and renal/hepatic insufficiency, serving primarily pharmaceutical and biotechnology companies that necessitate robust early phase research capabilities. Celerion generates revenue through its extensive portfolio of clinical research services, primarily structured around B2B transactions with pharmaceutical and biotechnology clients.

Revenue is realized upon completion of services rendered, with payments often tied to milestones during study processes. Key offerings, including trademarked services such as ClinQuick® and Celexus®, contribute significantly to the revenue stream, with contract pricing tailored to the specific needs of clients. The acquisition of Celerion, Inc. by H.

I. G. Capital in October 2022 is expected to support the company's next phase of growth. Future plans include the launch of new products and services aimed at enhancing their clinical research capabilities.

The company aims to expand into new geographic regions, specifically targeting Europe and Asia by late 2023. The recent funding will be utilized to accelerate these growth initiatives, ensuring Celerion remains competitive in the clinical research landscape.